The VA’s uptake of guideline-concordant surveillance for favorable-risk prostate cancer is remarkable, with active surveillance/watchful waiting rising from 27% to 93% for low-risk and 14% to 61% for favorable intermediate-risk disease from 2005–2024. | Lee, JAMA 2026
